<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965495</url>
  </required_header>
  <id_info>
    <org_study_id>YY_YYD302_001/2a</org_study_id>
    <nct_id>NCT02965495</nct_id>
  </id_info>
  <brief_title>Clinical Trial of YYD302 for Treatment of Osteoarthritis of the Knee</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YYD302 Once in the Treatment of Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blinded, parallel, placebo-controlled, phase I/IIa
      clinical trial of YYD302 for treatment of osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      phase I/IIa clinical trial of YYD302 for treatment of osteoarthritis of the knee
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of the Weight-bearing pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Change of the week 4 and 12 from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the KOOS scales on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of the rest pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motion pain (100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment (100mm-VAS) on the 4, 12 weeks after administration with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global assessment (100mm-VAS) on the 4, 12 weeks after administration</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the swelling in the knee joint from baseline to 4, 12 weeks after administration</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the tenderness on pressure in the knee joint from baseline to 4, 12 weeks after administration</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the Range Of Motion(ROM) in the knee joint on 4, 12 weeks after administration with baseline</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication count and the total amount on 4, 12 weeks</measure>
    <time_frame>Week 4 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of the Weight-bearing pain on 12 weeks in comparison with baseline</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of the OMERACT-OARSI on 12 weeks in comparison with baseline</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>YYD302 2ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YYD302 2ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YYD302 3ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YYD302 3ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 3ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate buffered saline 3ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD302 2ml</intervention_name>
    <description>YYD302 2ml</description>
    <arm_group_label>YYD302 2ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD302 3ml</intervention_name>
    <description>YYD302 3ml</description>
    <arm_group_label>YYD302 3ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 3ml</intervention_name>
    <description>phosphate buffered saline 3ml</description>
    <arm_group_label>Placebo 3ml</arm_group_label>
    <other_name>Placebo comparator 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or Females 40 years and older

          2. According to the clinical diagnosis standard of the American College of Rheumatology
             (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to
             over 3 conditions of followings.

               -  Over 50 years of age

               -  Less than 30 minutes of morning stiffness

               -  Crepitus on active motion

               -  4 bony tenderness

               -  Bony enlargement

               -  Nopalpable warmth of synvium

          3. Within 6 months from screening visit, someone who diagnosed with Kellgren &amp; Lawrence
             Grade I~III by the radioactive examination.

          4. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the
             single or both sides of the osteoarthritis is over 40mm

          5. Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or
             other pain-killers in the past.

          6. Patient who can walk by themselves without helper like cane or walker etc. (If the
             patient who has used helper routinely from previous 6 months, evaluating the patient
             including the helper is possible. In this case, patient needs to use same helper
             continuously by end of the clinical trial test.)

          7. Patient who agrees to participate in this clinical trial by themselves.

        Exclusion Criteria:

          1. Someone who has BMI≥32kg/m² at the screening visit.

          2. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can
             have an effect on pain sense over 3 months habitually.

          3. Patient who has been administrated gastrointestinal drug(for example H₂-blockers,
             misoprostol or proton pump inhibitors) regularly, who can't stop injecting for
             clinical study period.

          4. Patient has attended abnormal values from screening test(2 times excess at upper limit
             of the normal values at ALT, AST, BUN, Serum Creatinine).

          5. Patient who has rheumarthritis or other inflammatory metabolic arthritis.

          6. Patients having serious gastrointestinal, liver, renal, heart disease.

          7. When the inflammatory disease is occurred on joint area to patient like septic
             arthritis.

          8. Patients having skin ailment at the injecting site of the joint region.

          9. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis
             or systemic disease.

         10. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc
             herniation.

         11. Poly-articular patients who have suffered seriously by osteoarthritis at other parts
             affect judge of the knee joint pain.

         12. Patients who diagnosed clear interval disappearance at the knee joint by X-ray.

         13. Patients who were administrated below drugs before baseline visit.

               -  Patients who were injected HA at the target knee joint in recent 9 months.

               -  Patients who were injected HA at other parts of the knee joint in recent 6
                  months.

               -  Patients who were injected steroids into the intra-articular knee joint.

               -  Patients who were administrated steroids systemically by the oral medication
                  (But, except inhalation)

         14. Patients who have joint effusion trouble were judged as a positive by tests like
             Patella tap test.

         15. Patients who have target knee joint gotten surgical operation history including
             Arthroscopy within past one year (In case of having other side of knee joint or hip
             joint gotten surgical operation history, excepting the patients if there is
             possibility which can influence the target knee joint's appraisal.

         16. Patients who have an operation history about target knee joint.

         17. Patients who do the height weight aerobic exercise or anaerobic exercise.

         18. Patients who need to be administrated anticoagulant agent together(But, except 300mg
             daily dose aspirin)

         19. Patients who have hypersensitivity history about Investigational Product.

         20. In the midst of women in their childbearing years, patients who disagree to do *
             contraception by medically permitted method for 12 weeks from administrating
             investigational product.

             * The contraception by medically permitted method: Condom, In case of using injection
             or insertion, In case of installing a intrauterine contraception device etc.

         21. Patients who were injected other investigational product over a time within 30 days
             before participated in this clinical trail.

         22. Besides that, the patients who have difficulty to be participated in this clinical
             trial continuously by Principle Investigator (PI)'s decision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chul-Won Ha, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Department of Internal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

